• Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
  READ NEWS
• FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment
  READ NEWS
• FDA OKs new drug to treat all forms of hepatitis C
  READ NEWS
• Hepatitis C Virus Cases Nearly Triple in 5 years
  READ NEWS
• Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
  READ NEWS
• Hepatitis Tied to Parkinson’s Risk
  READ NEWS
• Cirrhosis Increasing Among Hepatitis C Patients, According to Large US Study
  READ NEWS
• Hepatitis C – Hepatitis Central.Com
  READ NEWS
• Primary care providers can effectively treat people with hepatitis C
  READ NEWS
• VA Study Confirms High Cure Rates With Use Of New Hepatitis C Drugs
  READ NEWS
• Hepatitis C virus and neurological damage
  READ NEWS
• Over 1 million treated with highly effective hepatitis C medicines
  READ NEWS
• Gilead and Massachusetts Agree to Rebates for Hep C Drugs
  READ NEWS
• FDA approves Epclusa
  READ NEWS
• Hepatitis C Antibody Screening in a Retail Pharmacy Setting: Local Testing and Linkage to Care via an HCV Management Specialist
  READ NEWS
• Covering Costly HCV Tx: Who Makes that Call?
  READ NEWS
• CDC Press Release: Hepatitis C Kills More Americans Than Any Other Infectious Disease
  READ NEWS
• HCV Testing: CDC Recommendations Miss 25% of Infections
  READ NEWS
• Merck's Zepatier shows high response rates in hep C trials
  READ NEWS
• New hepatitis C regimen shows high cure rates: studies
  READ NEWS
• Nearly one-third of patients with previous HCC recur after DAA therapy
  READ NEWS
• FDA Approves Merck’s New Hepatitis C Treatment
  READ NEWS
• AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
  READ NEWS
• AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
  READ NEWS
• AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
  READ NEWS
• AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
  READ NEWS
• Large Cure Rate for Patients with Hepatitis C May Have a Significant Impact on the Transplant Wait List
  READ NEWS
• Nearly Half of Hepatitis C Patients on Medicaid Denied Coverage for Life-Saving Drugs, Penn Researchers Report
  READ NEWS
• ALLY 3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin Demonstrates High Cure Rates in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis
  READ NEWS
• The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
  READ NEWS
• Early HCV fibrosis suggests need for early treatment
  READ NEWS
• Grazoprevir-elbasvir effective for hepatitis C in advanced chronic kidney disease
  READ NEWS
• Gilead's Hepatitis C Drug Works Against All Strains in Trial
  READ NEWS
• Therapy Respond Well to AbbVie Hepatitis C Treatment
  READ NEWS
• White House Under Pressure To Promote Better Access For Hepatitis C Drugs
  READ NEWS

SEE ALL NEWS ARTICLES